{"protocolSection": {"identificationModule": {"nctId": "NCT03555565", "orgStudyIdInfo": {"id": "Alogliptin-Met-5003"}, "secondaryIdInfos": [{"id": "JapicCTI-183979", "type": "REGISTRY", "domain": "JapicCTI"}], "organization": {"fullName": "Takeda", "class": "INDUSTRY"}, "briefTitle": "Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets \"Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age\"", "officialTitle": "Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets \"Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age\""}, "statusModule": {"statusVerifiedDate": "2023-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-02-28", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-10-31", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-10-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-06-01", "studyFirstSubmitQcDate": "2018-06-01", "studyFirstPostDateStruct": {"date": "2018-06-13", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-10-29", "resultsFirstSubmitQcDate": "2020-10-29", "resultsFirstPostDateStruct": {"date": "2020-11-23", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-08-29", "lastUpdatePostDateStruct": {"date": "2023-09-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Takeda", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this survey is to evaluate the long-term safety and efficacy of the alogliptin and metformin hydrochloride combination tablet in type 2 diabetes mellitus patients with renal impairment (mild), hepatic impairment (mild or moderate), or advanced age (65 years and more) in the routine clinical setting.", "detailedDescription": "The drug being tested in this survey is called alogliptin and metformin hydrochloride combination tablet. This tablet is being tested to treat people who have type 2 diabetes mellitus with renal impairment (mild), hepatic impairment (mild or moderate), or advanced age (65 years and more).\n\nThis survey is an observational (non-interventional) study and will look at the long-term safety and efficacy of the alogliptin and metformin hydrochloride combination tablet in the routine clinical setting. The planned number of observed patients will be approximately 600.\n\nThis multi-center observational trial will be conducted in Japan."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 1026, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Alogliptin and Metformin hydrochloride", "description": "Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.", "interventionNames": ["Drug: Alogliptin and Metformin hydrochloride"]}], "interventions": [{"type": "DRUG", "name": "Alogliptin and Metformin hydrochloride", "description": "Alogliptin and Metformin hydrochloride combination tablets", "armGroupLabels": ["Alogliptin and Metformin hydrochloride"], "otherNames": ["Inisync combination tablets"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants Who Had One or More Adverse Events", "description": "An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.", "timeFrame": "Up to 12 months"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c)", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final assessment point (up to Month 12) relative to baseline.", "timeFrame": "Baseline, up to final assessment point (up to Month 12)"}, {"measure": "Change From Baseline in Fasting Blood Glucose", "description": "The change in the value of fasting blood glucose collected at final assessment point (up to Month 12) relative to baseline.", "timeFrame": "Baseline, up to final assessment point (up to Month 12)"}, {"measure": "Change From Baseline in Fasting Insulin Level", "description": "The change in the value of fasting insulin collected at final assessment point (up to Month 12) relative to baseline.", "timeFrame": "Baseline, up to final assessment point (up to Month 12)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participants should meet one or more of the following:\n\n  1. Have renal impairment (mild)\n  2. Have hepatic impairment (mild or moderate)\n  3. Elderly (aged 65 years or more)\n\nExclusion Criteria:\n\n* Participants with any contraindication for study drug.", "healthyVolunteers": false, "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "Patients with type 2 diabetes mellitus for whom combination therapy with alogliptin and metformin hydrochloride is appropriate in the opinion of a physician as the routine medical care.", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Study Director", "affiliation": "Takeda", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Takeda Selected Site", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF", "CSR"], "accessCriteria": "IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.", "url": "https://vivli.org/ourmember/takeda/"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with a historical diagnosis of type 2 diabetes mellitus with renal or hepatic impairment or advanced age were enrolled. Participants received alogliptin and metformin hydrochloride combination tablets as part of a routine medical care.", "recruitmentDetails": "Participants took part in the survey at 115 investigative sites in Japan, from 28 February 2017 to 31 October 2019.", "groups": [{"id": "FG000", "title": "Alogliptin and Metformin Hydrochloride", "description": "Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1026"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1011"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}]}], "dropWithdraws": [{"type": "Case Report Forms Uncollected", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "13"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety Analysis Set, The safety analysis set was defined as all participants who completed the survey.", "groups": [{"id": "BG000", "title": "Alogliptin and Metformin Hydrochloride", "description": "Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "68.0", "spread": "11.33"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "402"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "609"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Japan", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1011"}]}]}]}, {"title": "Duration of Diagnosis of Type 2 Diabetes Mellitus", "description": "Mean duration between start of study and first time of diagnosis of type 2 diabetes mellitus was reported.", "populationDescription": "The number analyzed is the number of participants with data available for analysis.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "663"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "8.64", "spread": "7.297"}]}]}]}, {"title": "Weight", "populationDescription": "The number analyzed is the number of participants with data available for analysis.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms (kg)", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "692"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "66.13", "spread": "13.640"}]}]}]}, {"title": "BMI", "description": "Body Mass Index = weight (kg)/\\[height (m)\\^2\\]", "populationDescription": "The number analyzed is the number of participants with data available for analysis.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilogram (kg)/meter (m)^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "640"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "25.47", "spread": "3.996"}]}]}]}, {"title": "Renal Impairment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"title": "Had No Renal Impairment", "measurements": [{"groupId": "BG000", "value": "638"}]}, {"title": "Had Renal Impairment", "measurements": [{"groupId": "BG000", "value": "373"}]}]}]}, {"title": "Hepatic Impairment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"title": "Had No Hepatic Impairment", "measurements": [{"groupId": "BG000", "value": "545"}]}, {"title": "Had Hepatic Impairment", "measurements": [{"groupId": "BG000", "value": "466"}]}]}]}, {"title": "Healthcare Category", "description": "Participants were categorized as outpatient and inpatient.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"title": "Outpatient", "measurements": [{"groupId": "BG000", "value": "1006"}]}, {"title": "Inpatient", "measurements": [{"groupId": "BG000", "value": "5"}]}]}]}, {"title": "Predisposition to Hypersensitivity", "description": "Number of participants who had or did not have a liability or tendency to suffer from hypersensitivity was reported.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"title": "Had No Predisposition to Hypersensitivity", "measurements": [{"groupId": "BG000", "value": "826"}]}, {"title": "Had Predisposition to Hypersensitivity", "measurements": [{"groupId": "BG000", "value": "82"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "103"}]}]}]}, {"title": "Medical Complications", "description": "Complications defined as a disease or a health condition for each participant at the start of study. Complications were classified as congenital anomalies, endocrine disorders, hematologic disorders, psychiatric and nervous system disorders, cardiovascular disorders, respiratory disorders, gastrointestinal (GI) disorders, renal disease and other complications. Other complications included all complications except for those mentioned above.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"title": "Had No Medical Complications", "measurements": [{"groupId": "BG000", "value": "56"}]}, {"title": "Had Medical Complications", "measurements": [{"groupId": "BG000", "value": "955"}]}]}]}, {"title": "Medical History", "description": "Medical history defined as a disease or a health condition for each participant before start of the study. Medical history was classified as congenital anomalies, hematologic disorders, psychiatric and nervous system disorders, cardiovascular disorders, respiratory disorders, GI disorders, hepatic and biliary disorders, renal disease and other medical history. Other medical history included all medical history except for those mentioned above.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"title": "Had No Medical History", "measurements": [{"groupId": "BG000", "value": "629"}]}, {"title": "Had Medical History", "measurements": [{"groupId": "BG000", "value": "267"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "115"}]}]}]}, {"title": "Smoking Classification", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"title": "Never Smoked", "measurements": [{"groupId": "BG000", "value": "417"}]}, {"title": "Current Smoker", "measurements": [{"groupId": "BG000", "value": "156"}]}, {"title": "Ex-Smoker", "measurements": [{"groupId": "BG000", "value": "216"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "222"}]}]}]}, {"title": "Drinking Habits", "description": "Participants who answered Yes or No for a question \"Drink Alcohol Almost Every Day?\" were reported.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"title": "Yes", "measurements": [{"groupId": "BG000", "value": "246"}]}, {"title": "No", "measurements": [{"groupId": "BG000", "value": "570"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "195"}]}]}]}, {"title": "Employment Status", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"title": "Not Employed", "measurements": [{"groupId": "BG000", "value": "495"}]}, {"title": "Employed", "measurements": [{"groupId": "BG000", "value": "390"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "126"}]}]}]}, {"title": "Hemoglobin A1c (HbA1c) Level", "populationDescription": "The number analyzed is the number of participants with data available for analysis.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "912"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "7.336", "spread": "1.0710"}]}]}]}, {"title": "Alogliptin-Equivalent Dose per Day Given Immediate Before the Study Drug", "populationDescription": "The number analyzed is the number of participants with data available for analysis.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "576"}]}], "categories": [{"title": "< 25 milligrams (mg)", "measurements": [{"groupId": "BG000", "value": "14"}]}, {"title": "25 mg", "measurements": [{"groupId": "BG000", "value": "561"}]}, {"title": "> 25 mg", "measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Metformin-Equivalent Dose per Day Given Immediately Before the Study Drug", "populationDescription": "The number analyzed is the number of participants with data available for analysis.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "730"}]}], "categories": [{"title": "< 500 mg", "measurements": [{"groupId": "BG000", "value": "36"}]}, {"title": "500 mg", "measurements": [{"groupId": "BG000", "value": "505"}]}, {"title": "> 500 mg", "measurements": [{"groupId": "BG000", "value": "189"}]}]}]}, {"title": "Combination of Drugs for Type 2 Diabetes Mellitus Other than Alogliptin or Metformin", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1011"}]}], "categories": [{"title": "Not Combined", "measurements": [{"groupId": "BG000", "value": "401"}]}, {"title": "Combined", "measurements": [{"groupId": "BG000", "value": "610"}]}]}]}, {"title": "Status of Treatment Compliance to Alogliptin Medication Within 3 Months prior to the Study Drug", "populationDescription": "The number analyzed is the number of participants with data available for analysis.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "558"}]}], "categories": [{"title": "\u2265 90%", "measurements": [{"groupId": "BG000", "value": "487"}]}, {"title": "\u2265 70% and < 90%", "measurements": [{"groupId": "BG000", "value": "46"}]}, {"title": "\u2265 50% and < 70%", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "< 50%", "measurements": [{"groupId": "BG000", "value": "17"}]}]}]}, {"title": "Status of Treatment Compliance to Metformin Medication Within 3 Months prior to the Study Drug", "populationDescription": "The number analyzed is the number of participants with data available for analysis.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "717"}]}], "categories": [{"title": "\u2265 90%", "measurements": [{"groupId": "BG000", "value": "618"}]}, {"title": "\u2265 70% and < 90%", "measurements": [{"groupId": "BG000", "value": "67"}]}, {"title": "\u2265 50% and < 70%", "measurements": [{"groupId": "BG000", "value": "17"}]}, {"title": "< 50%", "measurements": [{"groupId": "BG000", "value": "15"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants Who Had One or More Adverse Events", "description": "An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.", "populationDescription": "Safety Analysis Set, The safety analysis set was defined as all participants who completed the survey.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Up to 12 months", "groups": [{"id": "OG000", "title": "Alogliptin and Metformin Hydrochloride", "description": "Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1011"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.93"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Glycosylated Hemoglobin (HbA1c)", "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final assessment point (up to Month 12) relative to baseline.", "populationDescription": "Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "Baseline, up to final assessment point (up to Month 12)", "groups": [{"id": "OG000", "title": "Alogliptin and Metformin Hydrochloride", "description": "Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "897"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.259", "spread": "0.9633"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Blood Glucose", "description": "The change in the value of fasting blood glucose collected at final assessment point (up to Month 12) relative to baseline.", "populationDescription": "Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "milligram/deciliter (mg/dL)", "timeFrame": "Baseline, up to final assessment point (up to Month 12)", "groups": [{"id": "OG000", "title": "Alogliptin and Metformin Hydrochloride", "description": "Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "468"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.08", "spread": "46.784"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Insulin Level", "description": "The change in the value of fasting insulin collected at final assessment point (up to Month 12) relative to baseline.", "populationDescription": "Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "microunit/milliliter (mcrU/mL)", "timeFrame": "Baseline, up to final assessment point (up to Month 12)", "groups": [{"id": "OG000", "title": "Alogliptin and Metformin Hydrochloride", "description": "Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.21", "spread": "13.852"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0.1", "timeFrame": "Up to 12 months", "description": "At each visit the investigator had to document any occurrence of AEs and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to the survey treatment.", "eventGroups": [{"id": "EG000", "title": "Alogliptin and Metformin Hydrochloride", "description": "Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.", "deathsNumAffected": 1, "deathsNumAtRisk": 1011, "seriousNumAffected": 4, "seriousNumAtRisk": 1011, "otherNumAffected": 13, "otherNumAtRisk": 1011}], "seriousEvents": [{"term": "Hepatocellular carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Large intestine polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}], "otherEvents": [{"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Bundle branch block right", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Chronic gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Cold sweat", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Drug eruption", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Muscular weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Renal disorder", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1011}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."}, "pointOfContact": {"title": "Study Director", "organization": "Takeda (Note: This product was divested to Teijin Pharma Limited in 2023)", "email": "TrialDisclosures@takeda.com", "phone": "+1-877-825-3327"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-06-01", "uploadDate": "2020-10-29T22:10", "filename": "Prot_000.pdf", "size": 10691285}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-03-26", "uploadDate": "2020-10-29T22:10", "filename": "SAP_001.pdf", "size": 1258123}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000520853", "term": "Alogliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Facial", "relevance": "HIGH"}, {"id": "M247106", "name": "Alogliptin", "asFound": "Reflex", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}